Completion of Vector Suite Ahead of Schedule

Completion of Vector Suite Ahead of Schedule

Despite the social distancing and supply chain challenges of the COVID-19 pandemic, the viral vector suite for Cobra Biologics has been completed 4-weeks ahead of schedule. Apreco is very proud to have been able to support BES Ltd.

Compliant to ACDP Hazard Group and US BioSafety Level 2, along with FDA, EMA and MHRA standards, the new facilities will allow Cobra to work with customers to develop gene therapy treatments for a range of life-limiting and life-threatening conditions.

#cdmo #viralvectors #clinicalresearch #biologics #facilitiesmanagement #pharmaceuticalindustry #supplychain #genetherapy #facilities #socialdistancing

Share this Post: Facebook Twitter Pinterest Google Plus StumbleUpon Reddit RSS Email

Comments are closed.